Member Info for Laura2022

Right at the end of the day is encouraging

Welcome HTBT

Click on the recent posts from Debull Kinghomer and myself if that helps

This is encouraging tho GB

Not only did this enable us to win a major new contract with an existing long-term Top 10 Pharma customer, it also opens a new technological offering, in line with our strategic goals.

Had a quick look GB etc

I took on board some posts from July

So will leave but looks good and great endorsement contract

Took SAR instead yesterday as lots near term catalysts ( see summary from someone yesterday morning

Good start aklee

Even at 2p (4 Million MC) its still a steal....lots of news to come to build from here.

* Highest Level of Revenue going into financial year £600k (We are 2 months into it)

* Dosemerx update & Collab

* NHS Prostate Cancer Trial ongoing - update due

* Beyond Blood Trial ongoing - update due (i would suggest people look at the shareholders on this one) Companies House

* Bicycle Therapeutics Update due - to be announced in September

* New Revenue Arm launched

* New Recruit has moved from AstraZeneca

* VAL 201 (Up to £6mil) if that ever ever ever happens who knows....

Great to hear Muck

Thanks Muck

Have you become an investor in PYC ?

Great if so to have new peooe here

Will have a quick look

Https://www.lse.co.uk/rns/PYC/publication-of-article-in-frontiers-in-oncology-u9lhuzwmhuqdusm.html

Yes Muck

And the increasing awareness amongst big pharmacy is growing due to the new regulations, and therefore so has PYC

1) New clients

2) repeat contracts with exisisting clients

3) PYC working on their LEAD compounds rather than just initial research

Pyc published a Optimus article in Frontiers magazine (see RNS early 2023)

Thanks for your insight

The Cash Offer represents a premium of approximately:

· 54.1 per cent. to the Closing Price of 740.0 pence per HL Share on 11 April 2024 (being the last Business Day before the Consortium's initial approach to the HL Board);

· 48.5 per cent. to the volume

Project renewal also fits directly into PYC precision dosing technology

Project Renewal also provides an opportunity to engage with the oncology community to improve awareness of FDA drug labeling as an information resource. 

Project Renewal is working to address this public health challenge by establishing a set of processes and procedures to inform regulatory decisions and update indications for use, dosage and administration, and other clinically significant information. As an extended part of the program, Project Renewal is also leveraging its experience from oncology to update labeling of older drugs in other disease areas.

Brilliant KingH

Yes GB

Those willing to hold for more than a day (like Earl seemingly) will have the golden tickets

Excellent post from Debull last night

21:28

Another X post today, this time regarding #ProjectOptimus and to me its the most bullish post PYC have put out in a long time??

https://x.com/Physiomics/status/1821529370311147843

"With #ProjectOptimus gaining traction, we’re learning that lower doses can be just as effective as higher ones while reducing side effects. This shift makes computer modelling more valuable than ever in getting the dose right first time."

they link it to this:

https://www.cancer.gov/news-events/cancer-currents-blog/2024/cancer-drugs-lower-doses

This was put on this site in early June 2024/

PYC then replied to their own post with this "At

@Physiomics

, we’re thrilled to contribute to this progress. Our expertise in quantitative and mechanistic modelling helps partners determine the optimal dose and schedule for First-in-Human trials. Reach out to learn more! #ProjectOptimus #PYC #pharma #biotech"

https://x.com/Physiomics/status/1821529372429287545

Thanks Muck/debuĺl

Cheers debull

Perfect that worked

Is there anything to glean from any of the 18 shareholders?

Are they connected people?

Thanks so much